The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells

Journal of Immunology

Volumn 189, Issue 2, 2012, Pages 567-574

  Chang, Li Yuan ^a,b   Lin, Yung Chang ^a,b   Kang, Chiao Wen ^a,b   Hsu, Chen Yu ^a,b   Chu, Yu Yi ^a   Huang, Ching Tai ^a,b   Day, Yuan Ji ^a,b   Chen, Tse Ching ^a,b   Yeh, Chau Ting ^a,b   Lin, Chun Yen ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; IMMUNOLOGIC MEMORY; INTEGRIN ALPHA CHAINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS; RECEPTORS, CCR5; T-LYMPHOCYTES, REGULATORY;

EID: 84863626453     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200266     Document Type: Article

References (34)

1. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787. (Pubitemid 351707693)
2. Tang, Q., and J. A. Bluestone. 2008. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244. (Pubitemid 351267321)
3. Lehmann, J., J. Huehn, M. de la Rosa, F. Maszyna, U. Kretschmer, V. Krenn, M. Brunner, A. Scheffold, and A. Hamann. 2002. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc. Natl. Acad. Sci. USA 99: 13031-13036.
4. Huehn, J., K. Siegmund, J. C. Lehmann, C. Siewert, U. Haubold, M. Feuerer, G. F. Debes, J. Lauber, O. Frey, G. K. Przybylski, et al. 2004. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199: 303-313. (Pubitemid 38252043)
5. Stephens, G. L., J. Andersson, and E. M. Shevach. 2007. Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J. Immunol. 178: 6901-6911. (Pubitemid 46847416)
6. Zhao, D., C. Zhang, T. Yi, C. L. Lin, I. Todorov, F. Kandeel, S. Forman, and D. Zeng. 2008. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 112: 2129-2138.
7. Sakaguchi, S., M. Miyara, C. M. Costantino, and D. A. Hafler. 2010. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10: 490-500.
8. Lin, Y. C., L. Y. Chang, C. T. Huang, H. M. Peng, A. Dutta, T. C. Chen, C. T. Yeh, and C. Y. Lin. 2009. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J. Immunol. 182: 6095-6104.
9. Anz, D., W. Mueller, M. Golic, W. G. Kunz, M. Rapp, V. H. Koelzer, J. Ellermeier, J. W. Ellwart, M. Schnurr, C. Bourquin, and S. Endres. 2011. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int. J. Cancer 129: 2417-2426.
10. Huehn, J., and A. Hamann. 2005. Homing to suppress: address codes for Treg migration. Trends Immunol. 26: 632-636. (Pubitemid 41628195)
11. Wei, S., I. Kryczek, and W. Zou. 2006. Regulatory T-cell compartmentalization and trafficking. Blood 108: 426-431. (Pubitemid 44061338)
12. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
13. Ma, B., W. Liu, R. J. Homer, P. J. Lee, A. J. Coyle, J. M. Lora, C. G. Lee, and J. A. Elias. 2006. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J. Immunol. 176: 4968-4978.
14. Chang, L. Y., Y. C. Lin, J. Mahalingam, C. T. Huang, T. W. Chen, C. W. Kang, H. M. Peng, Y. Y. Chu, J. M. Chiang, A. Dutta, et al. 2012. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72: 1092-1102.
15. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon- Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949. (Pubitemid 39273735)
16. Ishida, T., T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda. 2006. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66: 5716-5722. (Pubitemid 43927124)
17. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
18. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
19. Keibel, A., V. Singh, and M. C. Sharma. 2009. Inflammation, microenvironment, and the immune system in cancer progression. Curr. Pharm. Des. 15: 1949-1955.
20. Zamarron, B. F., andW. Chen. 2011. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7: 651-658.
21. Cepek, K. L., S. K. Shaw, C. M. Parker, G. J. Russell, J. S. Morrow, D. L. Rimm, and M. B. Brenner. 1994. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372: 190-193.
22. Suffia, I., S. K. Reckling, G. Salay, and Y. Belkaid. 2005. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 174: 5444-5455. (Pubitemid 40593184)
23. Mullaly, S. C., K. Burrows, F. Antignano, and C. Zaph. 2011. Assessing the role of CD103 in immunity to an intestinal helminth parasite. PLoS ONE 6: e19580.
24. Schuh, J. M., K. Blease, and C. M. Hogaboam. 2002. The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice. FASEB J. 16: 228-230.
25. Glass, W. G., J. K. Lim, R. Cholera, A. G. Pletnev, J. L. Gao, and P. M. Murphy. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202: 1087-1098. (Pubitemid 41464502)
26. Hardison, J. L., R. A. Wrightsman, P. M. Carpenter, W. A. Kuziel, T. E. Lane, and J. E. Manning. 2006. The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infect. Immun. 74: 135-143. (Pubitemid 43023067)
27. Colombo, M. P., and S. Piconese. 2007. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7: 880-887. (Pubitemid 350006256)
28. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
29. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59: 3128-3133. (Pubitemid 29316012)
30. Golgher, D., E. Jones, F. Powrie, T. Elliott, and A. Gallimore. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267-3275. (Pubitemid 35414884)
31. Comes, A., O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, and S. Ferrini. 2006. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176: 1750-1758. (Pubitemid 43134320)
32. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa, and C. J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832. (Pubitemid 32983017)
33. Quezada, S. A., K. S. Peggs, M. A. Curran, and J. P. Allison. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116: 1935-1945. (Pubitemid 44033317)
34. Gilliam, B. L., D. J. Riedel, and R. R. Redfield. 2011. Clinical use of CCR5 inhibitors in HIV and beyond. J. Transl. Med. 9(Suppl 1): S9.